Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406377 · ClinicalTrials.gov registry record · Phase 2
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT03406377 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 113 participants.
The verdict
NCT03406377, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.
Interventions
- DRUG Placebo
- DRUG OPK-88003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2019-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406377
The ClinicalTrials.gov registry entry for NCT03406377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03406377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03406377 about?
NCT03406377 is a clinical study titled "Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects". This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or treated with a stab...
What is the current status of trial NCT03406377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2018-04-02. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT03406377?
The interventions under investigation include: Placebo (DRUG), OPK-88003 (DRUG).
Who is sponsoring clinical trial NCT03406377?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.